

02/14/00  
JCS&S U.S. PTO

2-14-00

A  
C625 U.S.P.T.O.  
06/502945  
02/11/00

<p><b>UTILITY PATENT APPLICATION TRANSMITTAL</b> <i>(Only for new nonprovisional applications under 37 CFR 1.53(b))</i></p>	Attorney Docket No.	L0461/7081
	First Named Inventor or Application Identifier	
	Scanlan et al.	
	Express Mail Label No.	EL024661754US
Date of Deposit	February 11, 2000	

<b>APPLICATION ELEMENTS</b> <i>See MPEP chapter 600 concerning utility patent application contents</i>		<b>ADDRESS</b> TO: Assistant Commissioner for Patents Box Patent Application Washington, DC 20231
<p>1. <input checked="" type="checkbox"/> Fee Transmittal Form <i>(Submit an original, and a duplicate for fee processing)</i></p> <p>2. <input checked="" type="checkbox"/> Specification [Total pages 29] 16 pages description 1 page abstract 12 pages claims 56 claims</p> <p>3. Drawing(s) (35 USC 113) [Total sheets ___] <input type="checkbox"/> Informal <input type="checkbox"/> Formal [Total drawings ___]</p> <p>4. <input checked="" type="checkbox"/> Oath or Declaration [Total pages 3] a. <input type="checkbox"/> Newly executed (original or copy) b. <input checked="" type="checkbox"/> Copy from a prior application (37 CFR 1.63(d)) <i>(for continuation/divisional with Box 17 completed)</i> <i>[Note Box 5 below]</i></p> <p>i. <input type="checkbox"/> <u>DELETION OF INVENTOR(S)</u> Signed statement attached deleting inventor(s) named in the prior application, see 37 CFR 1.63(d)(2) and 1.33(b).</p> <p>5. <input checked="" type="checkbox"/> Incorporation by Reference <i>(usable if Box 4b is checked)</i> The entire disclosure of the prior application, from which a copy of the oath or declaration is supplied under Box 4b, is considered as being part of the disclosure of the accompanying application and is hereby incorporated by reference therein.</p>		
<b>ACCOMPANYING APPLICATION PARTS</b>		
<p>6. <input type="checkbox"/> Microfiche Computer Program (Appendix)</p> <p>7. <input checked="" type="checkbox"/> Nucleotide and/or Amino Acid Sequence Submission (if applicable, all necessary) a. <input checked="" type="checkbox"/> Computer Readable Copy <i>(see "other" below)</i> b. <input checked="" type="checkbox"/> Paper Copy (identical to computer copy) c. <input checked="" type="checkbox"/> Statement verifying identity of above copies</p> <p>8. <input type="checkbox"/> Assignment Papers (cover sheet &amp; documents(s))</p> <p>9. <input type="checkbox"/> 37 CFR 3.73(b) Statement <input type="checkbox"/> Power of Attorney <i>(when there is an assignee)</i></p> <p>10. <input type="checkbox"/> English Translation of Document <i>(if applicable)</i></p> <p>11. <input checked="" type="checkbox"/> Information Disclosure <input type="checkbox"/> Copies of IDS Statement (IDS)/PTO-1449 Citations</p> <p>12. <input checked="" type="checkbox"/> Preliminary Amendment</p> <p>13. <input checked="" type="checkbox"/> Return Receipt Postcard (MPEP 503) <i>(Should be specifically itemized)</i></p> <p>14. <input type="checkbox"/> Small Entity <input type="checkbox"/> Statement filed in prior Statement(s) application, Status still proper and desired</p> <p>15. <input type="checkbox"/> Certified Copy of Priority Document(s) <i>(if foreign priority is claimed)</i></p>		
<p>16. Other: Associate Power of Attorney; Letter requesting use of previous computer readable form; copy of computer disk label from previous case.</p> <p>17. If a CONTINUING APPLICATION, check appropriate box and supply the requisite information:</p> <p><input type="checkbox"/> Continuation <input checked="" type="checkbox"/> Divisional <input type="checkbox"/> Continuation-in-part (CIP) of prior application No.: 08/948,705</p> <p><input checked="" type="checkbox"/> Cancel in this application original claims 1-5, 7-36 and 41-56 of the prior application before calculating the filing fee.</p> <p><input checked="" type="checkbox"/> Amend the specification by inserting before the first line the sentence:  This application is a divisional of application serial no. 08/948,705, filed October 10, 1997, entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, and now pending.</p>		


Express Mail Label No:  
**EL024661754US**  
Date of Deposit: **2-11-00**

**18. CORRESPONDENCE ADDRESS**

Correspondence address below

<b>ATTORNEY'S NAME</b>	John R. Van Amsterdam, Reg. No. 40,212				
<b>NAME</b>	Wolf, Greenfield & Sacks, P.C.				
<b>ADDRESS</b>	600 Atlantic Avenue				
<b>CITY</b>	Boston	<b>STATE</b>	MA	<b>ZIP</b>	02210
<b>COUNTRY</b>	USA	<b>TELEPHONE</b>	(617) 720-3500	<b>FAX</b>	(617) 720-2441

**19. SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT REQUIRED**

<b>NAME</b>	John R. Van Amsterdam, Reg. No. 40,212
<b>SIGNATURE</b>	
<b>DATE</b>	FEBRUARY 11, 2000

Attorney's Docket No. L0461/7081

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant(s): Scanlan et al.  
Serial No: Unknown  
Filed: Herewith  
For: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON  
CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON  
CANCER  
Examiner: Not Assigned  
Art Unit: Unknown

Box Patent Application  
ASSISTANT COMMISSIONER FOR PATENTS  
WASHINGTON, D.C. 20231

Sir:

PRELIMINARY AMENDMENT

Please enter this Preliminary Amendment as follows:

In the Specification

On page 4, line 12, please delete "Applications Serial".

On page 4, lines 13-14, please delete "08/580,980 , and Application Serial No.

08/479,328, filed on June 7, 1995 and January 3, 1996, respectively" and insert --5,698,396-- therefor.

On page 4, line 14, please delete "All three" and insert --Both-- therefor.

On page 6, line 5, please delete "with the IgG then interacting".

On page 6, line 19, please delete "allowed U.S. Patent Application Serial No. 08/479,328" and insert --U.S. Patent 5,698,396-- therefor.

On page 9, line 18, please delete "300-400" and insert --300 to 400-- therefor.

On page 10, line 1, please delete "screening" and insert --screened-- therefor.

On page 10, line 20, please delete "breain" and insert --brain-- therefor.

On page 11, line 2, please delete "wherein," and insert --, wherein-- therefor.

In the Claims

Please cancel without prejudice claims 1-5, 7-36 and 41-56.

Please amend the claims as follows:

6.(amended) An [I]isolated protein encoded by [the] an isolated nucleic acid [of claim 1] molecule selected from the group consisting of:

(a) nucleic acid molecules which encode a cancer associated antigen, and which comprise a nucleotide sequence, the complementary sequence of which hybridizes, under stringent conditions, to at least one second nucleic acid molecule comprising a nucleotide sequence selected from the group consisting of the nucleotide sequences set forth as SEQ ID NOs: 1, 2, 3, 4, and 5,

(b) nucleic acid molecules that differ from the nucleic acid molecules of (a) in codon sequence due to the degeneracy of the genetic code, and

(c) complements of (a) or (b).

37.(amended) A composition of matter useful in stimulating an immune response to at least one protein encoded by at least one nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, said composition comprising a plurality of peptides derived from the amino acid sequence of said at least one protein, wherein said peptides bind to one or more MHC molecules presented on the surface of cells which express an abnormal amount of said at least one protein.

Please add the following new claims:

57. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:1.

58. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:2.

59. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:3.

60. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:4.

61. The isolated protein of claim 6, wherein the nucleic acid molecule comprises SEQ ID NO:5.

62. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:1.

63. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:2.

64. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:3.

65. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:4.

66. The composition of matter of claim 37, wherein the at least one nucleic acid molecule comprises the nucleotide sequence set forth in SEQ ID NO:5.


67. The composition of matter of claim 37, wherein at least one of the plurality of peptides is coupled to an immune response stimulating compound.

#### REMARKS

Please enter this Preliminary Amendment before calculating the fees. Applicants have deleted all claims but those corresponding to claim group number 2 (claims 6 and 37-40) as set forth in the restriction requirement mailed on October 1, 1998 in the parent case, serial number 08/948,705. Amendments to the Specification are the same as made in the parent application.

New claims 57-61 and 62-66 are derived from original claims 6 and 37, respectively. Support for new claim 67 can be found in the Specification at page 14, line 16. No new matter has been added.

Respectfully submitted,



---

John R. Van Amsterdam  
Reg. No. 40,212  
WOLF, GREENFIELD & SACKS, P.C.  
600 Atlantic Avenue  
Boston, MA 02210  
Tel. (617)720-3500

ATTORNEY DOCKET NO. L0461/7081

Date: February **11**, 2000

xNDD

DRAFT - NOT FOR FILING

JUD 5506-JEL/NDH

Express Mail Label No.  
EL024661754US  
Date of Deposit: 2-11-00

**ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH  
COLON CANCER AND METHODS FOR DIAGNOSING AND  
TREATING COLON CANCER**

**FIELD OF THE INVENTION**

This invention relates to the isolation of genes associated with colon cancer, methods of diagnosing colon cancer using these, as well as other genes which are known, as well as therapeutic approaches to treating such conditions.

5

**BACKGROUND AND PRIOR ART**

It is fairly well established that many pathological conditions, such as infections, cancer, autoimmune disorders, etc., are characterized by the inappropriate expression of certain molecules. These molecules thus serve as "markers" for a particular pathological or abnormal condition. Apart from their use as diagnostic "targets", i.e., materials to be identified to diagnose these abnormal conditions, the molecules serve as reagents which can be used to generate diagnostic and/or therapeutic agents. A by no means limiting example of this is the use of cancer markers to produce antibodies specific to a particular marker. Yet another non-limiting example is the use of a peptide which complexes with an MHC molecule, to generate cytolytic T cells against abnormal cells.

10  
15

Preparation of such materials, of course, presupposes a source of the reagents used to generate these. Purification from cells is one laborious, far from sure method of doing so. Another preferred method is the isolation of nucleic acid molecules which encode a particular marker, followed by the use of the isolated encoding molecule to express the desired molecule.

20

To date, two strategies have been employed for the detection of such antigens, in e.g., human tumors. These will be referred to as the genetic approach and the biochemical

approach. The genetic approach is exemplified by, e.g., dePlaen et al., Proc. Natl. Sci. USA 85: 2275 (1988), incorporated by reference. In this approach, several hundred pools of plasmids of a cDNA library obtained from a tumor are transfected into recipient cells, such as COS cells, or into antigen-negative variants of tumor cell lines. Transfectants are  
5 screened for the expression of tumor antigens via their ability to provoke reactions by anti-tumor cytolytic T cell clones. The biochemical approach, exemplified by, e.g., Mandelboim, et al., Nature 369: 69 (1994) incorporated by reference, is based on acidic elution of peptides which have bound to MHC-class I molecules of tumor cells, followed by reversed-phase high performance liquid chromatography (HPLC). Antigenic peptides are  
10 identified after they bind to empty MHC-class I molecules of mutant cell lines, defective in antigen processing, and induce specific reactions with cytolytic T-lymphocytes ("CTLs"). These reactions include induction of CTL proliferation, TNF release, and lysis of target cells, measurable in an MTT assay, or a <sup>51</sup>Cr release assay.

These two approaches to the molecular definition of antigens have the following disadvantages: first, they are enormously cumbersome, time-consuming and expensive; second, they depend on the establishment of CTLs with predefined specificity; and third, their relevance in vivo for the course of the pathology of disease in question has not been proven, as the respective CTLs can be obtained not only from patients with the respective disease, but also from healthy individuals, depending on their T cell repertoire.  
15

The problems inherent to the two known approaches for the identification and molecular definition of antigens is best demonstrated by the fact that both methods have, so far, succeeded in defining only very few new antigens in human tumors. See, e.g., van der

Bruggen et al., Science 254: 1643-1647 (1991); Brichard et al., J. Exp. Med. 178: 489-495 (1993); Coulie, et al., J. Exp. Med. 180: 35-42 (1994); Kawakami, et al., Proc. Natl. Acad. Sci. USA 91: 3515-3519 (1994).

Further, the methodologies described rely on the availability of established, permanent cell lines of the cancer type under consideration. It is very difficult to establish cell lines from certain cancer types, as is shown by, e.g., Oettgen, et al., Immunol. Allerg. Clin. North. Am. 10: 607-637 (1990). It is also known that some epithelial cell type cancers are poorly susceptible to CTLs in vitro, precluding routine analysis. These problems have stimulated the art to develop additional methodologies for identifying cancer associated antigens.

10  
15

20

One key methodology is described by Sahin, et al., Proc. Natl. Acad. Sci. USA 92: 11810-11913 (1995), incorporated by reference. Also, see U.S. Patent Applications Serial No. 08/580,980, and Application Serial No. 08/479,328, filed on June 7, 1995 and January 3, 1996, respectively. All three of these references are incorporated by reference. To summarize, the method involves the expression of cDNA libraries in a prokaryotic host. (The libraries are secured from a tumor sample). The expressed libraries are then immunoscreened with absorbed and diluted sera, in order to detect those antigens which elicit high titer humoral responses. This methodology is known as the SEREX method ("Serological identification of antigens by Recombinant Expression Cloning"). The methodology has been employed to confirm expression of previously identified tumor associated antigens, as well as to detect new ones. See the above referenced patent applications and Sahin, et al., supra, as well as Crew, et al., EMBO J 144: 2333-2340

(1995).

The SEREX methodology has now been applied to colon cancer samples. Several nucleic acid molecules have been newly isolated and sequenced, and are now associated with stomach cancer. Further, a pattern of expression involving these, as well as previously isolated genes has been found to be associated with colon cancer. These results are the subject of this application, which is elaborated upon in the disclosure which follows.

#### DETAILED DESCRIPTION OF PREFERRED EMBODIMENTS

##### Example 1

Tumor samples were obtained as surgical samples, and were frozen at -80°C until ready for use.

Total RNA was then isolated from the samples, using the well known guanidium thiocyanate method of Chirgwin, et al., Biochemistry 18: 5294-5299 (1979), incorporated by reference. The thus obtained total RNA was then purified to isolate all poly A<sup>+</sup> RNA, using commercially available products designed for this purpose.

The poly A<sup>+</sup> RNA was then converted into cDNA, and ligated into λZAP, a well known expression vector.

Three cDNA libraries were constructed in this way, using colorectal carcinoma samples. A fourth library, also from colorectal carcinoma, was prepared, albeit in a different way. The reasons for this difference will be clear in the examples, infra.

The fourth library was an IgG subtraction library, prepared by using a subtraction partner, generated by PCR amplification of a cDNA clone which encoded an IgG molecule.

See, e.g., Ace et al, Endocrinology 134: 1305-1309 (1994), and incorporated by reference in its entirety.

This is done to eliminate any false, positive signals resulting from interaction of cDNA clones which encode IgG, with the IgG then interacting with the anti-human IgG used in the assay, as described infra. PCR product was biotinylated, and hybridized with denatured second strand cDNA, at 68°C for 18 hours. Biotinylated hybrid molecules were coupled to streptavidin, and then removed by phenol chloroform extraction. Any remaining cDNA was also ligated into λZAP. All libraries were amplified, prior to immunoscreening discussed infra.

#### Example 2

Immunoscreening was carried out, using sera obtained from patients undergoing routine diagnostic and therapeutic procedures. The sera were stored at -70°C prior to use. Upon thawing, the sera were diluted at 1:10 in Tris buffered saline (pH 7.5), and were then passed through Sepharose 4B columns. First, the sera were passed through columns which had E. coli Y1090 lysates coupled thereto, and then lysates from bacteriophage infected E. coli BNN97 lysates. Final serum dilutions were then prepared in 0.2% non-fat dried milk/Tris buffered saline.

The method of Sahin et al., Proc. Natl. Acad. Sci. USA 92: 11810-11813 (1995), and allowed U.S. patent application Serial No. 08/479,328, both of which are incorporated by reference, was used, with some modifications. Specifically recombinant phage at a concentration of  $4 \times 10^3$  phages per 15 cm plate (pfus), were amplified for six hours, after

which they were transferred to nitrocellulose membranes for 15 hours. Then, the membranes were blocked with 5% nonfat dried milk.

As an alternative to the IgG subtraction, discussed supra, membranes were prescreened in a 1:2000 dilution of peroxidase conjugated, Fc fragment specific goat anti-human IgG, for one hour, at room temperature. Color was developed using 3,3-diaminobenzidine tetrahydrochloride, which permitted scoring of IgG encoding clones.

Membranes were then incubated in 1:100 dilutions of autologous sera, which had been pretreated with the Sepharose 4B columns, as described supra. The filters were then incubated, in a 1:3000 dilution of alkaline phosphatase conjugated Fc fragment specific, goat anti-human IgG, for one hour, at room temperature. The indicator system 4-nitroblue tetrazolium chloride/5-bromo-4-chloro-3-indolyl-phosphate was then added, and color development assessed. Any positive clones were subcloned, and retested, except the time on the nitrocellulose membrane was reduced to three hours. A total of forty-eight positive clones were identified.

Analysis of probes for SEQ ID NOS: 1 and 2 confirmed their universal expression.

### Example 3

Example 2 described work using autologous serum. The positive clones were then rescreened, using allogeneic serum, following the same method discussed supra, in example 2, except IgG prescreening was omitted. The allogeneic sera was obtained from sixteen normal blood donors, and twenty nine patients who had been diagnosed with colorectal cancer.

The analysis with the two types of serum revealed that fourteen reacted with a subset of sera from normal and cancer patients, twenty-eight only with autologous sera, and six with both allogeneic and autologous sera. Over 60% of the allogeneic serum samples tested reacted with at least one of these positive clones. About 20% reacted with two or more.

5

#### Example 4

In view of the results described in example 3, further experiments were carried out using serum samples from patients with other forms of cancer, i.e., renal cancer (13 samples), lung cancer (23 samples), and breast cancer (10 samples). The results are set forth in Table I which follow:

Clone Number	Normal Sera	Colon Cancer	Renal Cancer	Lung Cancer	Breast Cancer
NY-Co-8	0/16	8/29	1/13	0/23	0/10
NY-Co-9	0/16	5/29	1/13	1/23	0/10
NY-Co-13	0/16	5/29	0/13	0/23	0/10
NY-Co-16	0/16	3/29	0/13	0/23	0/10
NY-Co-20	0/16	4/29	0/13	0/23	0/10
NY-Co-38	0/16	4/29	3/13	0/23	1/10

Example 5

Following the screening work described supra, the cDNA inserts were purified and sequenced, following standard methods.

Of the six clones which were identified as being reactive with autologous and allogeneic cancer serum, and not with normal serum, two were found to be identical to previously identified molecules. Four others were found to have little or no homology to known sequences. These are presented as SEQ ID NOS: 1-4. Of twenty seven allogeneic colon cancer serum samples tested, 67% reacted with at least one of these antigens.

Example 6

The expression pattern of mRNA corresponding to SEQ ID NOS: 1, 2 and 4, as well as other sequences identified via the preceding examples was determined. To do this, RT-PCR was carried out on a panel of RNA samples, taken from normal tissue. The panel contained RNA of lung, testis, small intestine, colon, breast, liver and placenta tissues. The RNA was purchased from a commercial source. RNA from a colon tumor sample was also included. All samples were set up for duplicate runs, so that genomic DNA contamination could be accounted for. In the controls, no reverse transcriptase was used.

Primers were designed which were specific for the cDNA, which would amplify 5'-fragments, from 300-400 base pairs in length. The PCR reactions were undertaken at an annealing temperature of 68°C. Where appropriate, 5' and 3'-RACE reactions were undertaken, using gene specific primers, and adapter primers, together with commercially available reagents. Specifically, SEQ ID NOS: 2 and 4 were tested using RACE. The

resulting products were subcloned into vector pCR 2.1, screening via PCR using internal primers, and then sequenced.

SEQ ID NOS: 1 and 2 were found to be amplified in all tissues tested. SEQ ID NO: 4 was found in colon tumor, colon metastasis, gastric cancer, renal cancer and colon cancer cell lines Colo 204 and HT29, as well as in normal colon, small intestine, brain, stomach, testis, pancreas, liver, lung, heart, fetal brain, mammary gland, bladder, adrenal gland tissues. It is was not found in normal uterine, skeletal muscle, peripheral blood lymphocytes, placental, spleen thymus, or esophagus tissue, nor in lung cancer.

The analysis also identified differential expression of a splice variant of SEQ ID NO: 4, i.e., SEQ ID NO: 5. When the two sequences were compared, it was found that SEQ ID NO: 4 encodes a putative protein of 652 amino acids, and molecular weight of 73,337 daltons. SEQ ID NO: 5, in contrast, lacks an internal 74 base pairs, corresponding to nucleotides 1307-1380 of SEQ ID NO: 4. The deletion results in formation of a stop codon at the splice function, and a putative protein of 404 amino acids, and molecular weight 45,839. The missing segment results in the putative protein lacking a PEST protein degradation sequence, thereby suggesting a longer half life for this protein.

In additional experiments, primers designed not to differentiate between SEQ ID NOS: 4 and 5 resulted in almost universal amplification (placenta being the only exception). In contrast, when primers specific for SEQ ID NO: 5 were used differences were seen in normal pancreatic, liver, lung, heart, fetal breain, mammary gland, bladder, and adrenal gland tissue, where there was no expression of SEQ ID NO: 5 found.

Example 7

Northern blotting was also carried out for SEQ ID NOS: 1, 2, 4 and 5. To do this, the same commercially available RNA libraries discussed supra were used.

Samples (2 ug) of polyA<sup>+</sup> RNA were analyzed from these samples, using random, <sup>32</sup>P labelled probes 300-360 nucleotides in length, obtained from PCR products. These probes were hybridized to the RNA, for 1.5 hours, at 68°C, followed by two washes at 0.1xSSC, 0.1% SDS, 68°C, for 30 minutes each time.

SEQ ID NOS: 1 and 2 were again found to be universally expressed.

Example 8

Further screening identified additional isoforms of SEQ ID NOS: 1 and 4. These are set forth as SEQ ID NOS: 6, 7 and 8. The isoform represented by SEQ ID NO: 6 is a naturally occurring splice variant of SEQ ID NO: 1, found in normal colon. SEQ ID NO: 7, which is an isoform of SEQ ID NO: 4, was found in brain tissue, primarily spinal chord and medulla. SEQ ID NO: 8, was found in normal kidney and in colon tumors, metastasized colon cancer, gastric cancer, and in colon cancer cell line Colo 205. It was not found in any normal tissue other than kidney.

The foregoing examples demonstrate several features of the invention. These include diagnostic methods for determining presence of transformed cells, such as colon cancer cells, in a sample. The sample may contain whole cells or it may be, e.g., a body fluid sample, or an effusion, etc., where the sample may contain cells, but generally will contain shed antigen. The experiments indicate that there is a family of proteins, expression of which is

associated with colon cancer. Hence, the invention involves, inter alia, detecting at least two of the proteins encoded by any of SEQ ID NOS: 1-5 wherein, presence of these is indicative of a pathology, such as colon cancer or other type of related condition. Exemplary of the type of diagnostic assays which can be carried out are immunoassays, amplification assays (e.g., PCR), or, what will be referred to herein as a "display array". "Display array" as used herein refers to a depiction of the protein profile of a given sample. Exemplary of such displays are 2-dimensional electrophoresis, banding patterns such as SDS-gels, and so forth.

5 Thus, one aspect of the invention involves diagnosing colon cancer or a related condition by determining protein display of a sample, wherein a determination of at least one of the proteins, or expression of their genes, is indicative of colon cancer or a related condition.

10 There are many ways to carry out these assays. For example, as indicated herein, antibodies to the proteins were found in patient samples. One can assay for these antibodies using, e.g., the methodology described herein, or by using a purified protein or proteins or antigenic fragment thereof, and so forth. One can also assay for the protein itself, using antibodies, which may be isolated from samples, or generated using the protein and standard techniques. This antibodies can then be labelled, if desired, and used in standard immunoassays. These antibodies or oligonucleotide probes/primers may also be used to examine biopsied tissue samples, e.g., to diagnose precancerous conditions, early stage cancers, and so forth.

15

20 Similarly, any and all nucleic acid hybridization systems can be used, including amplification assays, such as PCR, basic probe hybridization assays, and so forth. The antibodies, such as polyclonal antibodies, monoclonal antibodies, the hybridomas which

produce them, recombinantly produced antibodies, binding fragments of these, hybridization kits, DNA probes, and so forth, are all additional features of the invention.

Any of these assays can also be used in progression/regression studies. One can monitor the course of an abnormality such as colon cancer which involve expression of any one of the proteins, the expression of which is governed by the nucleic acid molecules SEQ ID NOS: 1-5, simply by monitoring levels of the protein, its expression, and so forth using any or all of the methods set forth supra.

As has been indicated supra, the isolated nucleic acid molecules which comprise the nucleotide sequences set forth in SEQ ID NOS: 1-5 are new, in that they have never been isolated before. These nucleic acid molecules may be used as a source to generate colon cancer specific proteins and peptides derived therefrom, and oligonucleotide probes which can themselves be used to detect expression of these genes. Hence, a further aspect of the invention is an isolated nucleic acid molecule which comprises any of the nucleotide sequences set forth in SEQ ID NOS: 1-5, or molecules whose complements hybridize to one or more of these nucleotide sequences, under stringent conditions, expression vectors comprising these molecules, operatively linked to promoters, cell lines and strains transformed or transfected with these, and so forth. "Stringent conditions", is used herein, refers to condition such as those specified in U.S. Patent No. 5,342,774, i.e., 18 hours of hybridization at 65°C, followed by four one hour washes at 2xSSC, 0.1% SDS, and a final wash at 0.2xSSC, more preferably 0.1xSSC, 0.1% SDS for 30 minutes, as well as alternate conditions which afford the same level of stringency, and more stringent conditions.

It should be clear that these methodologies may also be used to track the efficacy of a

therapeutic regime. Essentially, one can take a baseline value for the protein or proteins being tested, using any of the assays discussed supra, administer a given therapeutic, and then monitor levels of the protein or proteins thereafter, observing changes in protein levels as indicia of the efficacy of the regime.

5           The identification of the proteins and nucleic acid molecules set forth herein as being implicated in pathological conditions such as colon cancer also suggests a number of therapeutic approaches to such conditions. The experiments set forth supra establish that antibodies are produced in response to expression of these proteins, suggesting their use as a vaccine. Hence, a further embodiment of the invention is the treatment of conditions which are characterized by expression of one or more of the subject proteins, via immunotherapeutic approaches. One of these approaches is the administration of an amount of one or more these proteins, or an immunogenic peptide derived therefrom in an amount sufficient to provoke or augment an immune response. The proteins or peptides may be combined with one or more of the known immune adjuvants, such as saponins GM-CSF interleukins, and so forth. If the peptides are too small to generate a sufficient antibody response, they can be coupled to the well known conjugates used to stimulate responses.

10           Similarly, the immunotherapeutic approaches include administering an amount of inhibiting antibodies sufficient to inhibit the protein or proteins. These antibodies may be, e.g., antibodies produced via any of the standard approaches elaborated upon supra.

15

20           T cell responses may also be elicited by using peptides derived from the proteins which then complex, non-covalently, with MHC molecules, thereby stimulating proliferation of cytolytic T cells against any such complexes in the subject. It is to be noted that the T

cells may also be elicited in vitro, and then reperfused into the subject being treated.

Note that the generation of T cells and/or antibodies can also be accomplished by administering cells, preferably treated to be rendered non-proliferative, which present relevant T cell or B cell epitopes for response.

5       The therapeutic approaches may also include gene therapies, wherein an antisense molecule, preferably from 10 to 100 nucleotides in length, is administered to the subject either "neat" or in a carrier, such as a liposome, to facilitate incorporation into a cell, followed by inhibition of expression of the protein. Such antisense sequences may also be incorporated into appropriate vaccines, such as in viral vectors (e.g., Vaccinia), bacterial constructs, such as variants of the well known BCG vaccine, and so forth.

An additional DNA based therapeutic approach is the use of a vector which comprises one or more nucleotide sequences, preferably a plurality of these, each of which encodes an immunoreactive peptide derived from the expressed proteins. One can combine these peptides expressing sequences in all possible variations, such as one from each protein, several from one or more protein and one from each of the additional proteins, a plurality from some and none from others, and so forth.

Other features of the invention will be clear to the skilled artisan, and need not be repeated here.

20      The terms and expressions which have been employed are used as terms of description and not of limitation, and there is no intention in the use of such terms and expressions of excluding any equivalents of the features shown and described or portions

PCT/US2003/034215

thereof, it being recognized that various modifications are possible within the scope of the invention.

**We Claim:**

1. An isolated nucleic acid molecule which comprises a nucleotide sequence, the complementary sequence of which hybridizes, under stringent conditions to at least one nucleic acid molecule having a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5.
2. Expression vector comprising the isolated nucleic acid molecule of claim 1, operably linked to a promoter.
3. Cell line or cell strain, transformed or transfected with the isolated nucleic acid molecule of claim 1.
4. Cell line or cell strain, transformed or transfected with the expression vector of claim 2.
5. The isolated nucleic acid molecule of claim 1, which consists of a nucleotide sequences set forth at SEQ ID NO: 1, 2, 3, 4 or 5.
6. Isolated protein encoded by the isolated nucleic acid molecule of claim 1.
7. Method for determining colon cancer in a sample, comprising assaying said sample for expression of the isolated nucleic acid molecule of claim 1, presence thereof being indicative of colon cancer.

8. Method for determining colon cancer in a sample, comprising assaying said sample for a protein encoded by the isolated nucleic acid molecule of claim 1, presence of said protein being indicative of colon cancer in said sample.

9. The method of claim 8, comprising assaying said sample for a peptide derived from said protein.

10. Composition of matter useful in treating colon cancer, comprising the isolated nucleic acid molecule of claim 1, and a pharmaceutically acceptable carrier.

11. Composition of matter useful in treating colon cancer, comprising therapeutically effective amount of the expression vector of claim 2, and a pharmaceutically acceptable carrier.

12. Composition of matter useful in treating colon cancer, comprising a therapeutically effective amount of the cell line or cell strain of claim 3, and having presented on its surface, a peptide complexed to an MHC molecule to form a complex which provokes an immune response against colon cancer cells.

13. A method for treating a subject afflicted with a colon cancer or related disorder, comprising:

(i) removing an immunoreactive cell containing sample from said subject,

(ii) contacting the immunoreactive cell containing sample to the cell line or cell strain of claim 3 conditions favoring production of cytolytic T cells against a peptide derived from the proteins encoded by the isolated nucleic acid molecule used to transfect or transform said cell, and

(iii) introducing said cytolytic T cells to said subject in an amount sufficient to lyse said cells.

14. A method for treating a subject afflicted with colon cancer or related condition, comprising:

(i) identifying a gene expressed by cancer cells associated with said colon cancer or related condition, wherein said gene comprises at least one nucleotide sequence set forth in SEQ ID NOS: 1-5;

(ii) identifying an MHC molecule which presents a portion of an expression product of said gene;

(iii) transfected a host cell having the same molecule as identified in (ii) with said gene;

(iv) culturing said transfected cells to express said gene, and;

(v) introducing an amount of said cells to said subject sufficient to provoke an immune response against said cancer cells.

15. The method of claim 14, wherein said immune response comprises a B-cell response.

16. The method of claim 14, wherein said immune response comprises a T-cell response.

17. The method of claim 15, wherein said B cell response comprises production of antibodies specific to said expression product or peptide derived therefrom.

18. The method of claim 16, wherein said T-cell response comprises generation of cytolytic T-cell specific for cells presenting said peptide.

19. The method of claim 14, further comprising treating said cells to render them non-proliferative.

20. A method for treating a subject with a cancerous condition characterized by abnormal amounts of a protein, comprising:

- (i) identifying a gene expressed by said abnormal cells, comprising at least one nucleotide sequence set forth in SEQ ID NOS: 1-5;
- (ii) transfecting a host cell having the same MHC type as said patient expressing said gene;
- (iii) culturing said transfected cells to express said gene, and;
- (iv) introducing an amount of said cells to said subject sufficient to provoke an immune response against said cancerous condition.

21. The method of claim 20, further comprising treating said cells to render them non proliferative.

22. A method for treating a subject with a condition characterized by abnormal amounts of protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject an amount of a cell transfected with (i) a nucleic acid molecule which codes for said protein and (ii) a nucleic acid sequence which codes for an MHC molecule which presents a peptide derived from said protein wherein said peptide is presented by cells associated with said condition, sufficient to alleviate said condition.

23. Method of claim 22, further comprising treating said cell to render it non-proliferative.

24. A method for treating a subject afflicted with a condition characterized by an abnormal amount of protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject an amount of a reagent consisting essentially of non-proliferative cells having expressed on its surface a peptide characteristic of said abnormal cells in an amount sufficient to elicit an immune response thereto.

25. A method for treating a subject afflicted with a condition characterized by an abnormal amount of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject an antibody which specifically binds to said protein or a peptide derived therefrom, said antibody being coupled to a therapeutically useful agent, in an amount sufficient to treat said condition.

26. A method for treating a subject afflicted with a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject a sample of non-proliferative cells which express said protein in an amount sufficient to alleviate said condition.

27. A method for preventing onset of a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, in a subject comprising administering an amount of a vaccine comprising said protein and an adjuvant in an amount sufficient to prevent onset of said cancerous condition in said subject.

28. A method for preventing onset of a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, in a subject comprising administering an amount of a vaccine

comprising a peptide derived from said protein in an amount sufficient to prevent onset of said condition in said subject.

29. A method for preventing onset of a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, in a subject comprising administering an amount of a vector which comprises a gene encoding said protein to a cell which is capable of expressing said protein or presenting a peptide derived therefrom, in an amount sufficient to prevent onset of said cancerous condition in said subject.

30. A method for treating a subject afflicted with a condition characterized by abnormal amounts of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising:

- (i) identifying cells from said subject which express abnormal amounts of said protein;
- (ii) isolating a sample of said cells;
- (iii) cultivating said cell, and
- (iv) introducing said cells to said subject in an amount sufficient to provoke an immune response against said cells.

31. The method of claim 30, further comprising rendering said cells non proliferative, prior to introducing them to said subject.

32. A method for treating a subject with a condition characterized by abnormal amounts of at least one protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in any of SEQ ID NO: 1, 2, 3, 4 or 5, comprising administering to said subject a vector which comprises a sequence encoding at least one immunoreactive peptide derived from said at least one protein, to a cell capable of expressing and presenting said at least one peptide, in an amount sufficient to induce an immune response in said subject.

33. A method for following progress of a therapeutic regime designed to alleviate a condition characterized by abnormal expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5, comprising:

(a) assaying a sample from a subject to determine level of a parameter selected from the group consisting of (i) a peptide derived from said protein, (ii) a cytolytic T cell specific for cells presenting said peptide, and (iii) an antibody which specifically binds to said peptide of said protein, at a first time period;

(b) assaying level of the parameter selected in (a) at a second period of time and comprising it to the level determined in (a) as a determination of effect of said therapeutic regime.

34. A method for treating a pathological cell condition characterized by aberrant expression of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth at SEQ ID NO: 1, 2, 3, 4 or 5 associated with said condition, comprising

administering to a subject in need thereof an effective amount of either: (a) a protein inhibitor, or (b) an inhibitor of gene expression of said protein.

35. The method of claim 34, wherein said protein inhibitor is an inhibiting antibody.

36. The method of claim 34, wherein said inhibitor of gene expression is an antisense molecule.

37. A composition of matter useful in stimulating an immune response to a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, comprising a plurality of peptides derived from the amino acid sequence of said protein, wherein said peptides bind to one or more MHC molecules presented on the surface of cells which express an abnormal amount of said protein.

38. The composition of matter of claim 37, wherein at least a portion of said plurality of peptides bind to MHC molecules and elicit a cytolytic response thereto.

39. The composition of matter of claim 38, further comprising an adjuvant.

40. The composition of matter of claim 39, wherein said adjuvant is a saponin, GM-CSF, or an interleukin.

41. An isolated antibody which binds to a protein encoded by a nucleic acid molecule which comprises the nucleotide sequence of any of SEQ ID NO: 1, 2, 3, 4 or 5.

42. The isolated antibody of claim 41, wherein said antibody is a monoclonal antibody.

43. An isolated antibody which specifically binds to a peptide derived from a protein encoded by a nucleic acid molecule which comprises a nucleotide sequence set forth in any of SEQ ID NO: 1, 2, 3, 4 or 5.

44. The antibody of claim 43, wherein said antibody is a monoclonal antibody.

45. An isolated antibody which specifically binds to a complex of (i) a peptide derived from protein encoded by a nucleic acid molecule which comprises a nucleotide sequence set forth in any of SEQ ID NO: 1, 2, 3, 4 or 5 and (ii) an MHC molecule to which said peptide complexes, but does not bind to (i) or (ii) alone.

46. The antibody of claim 45, wherein said antibody is a monoclonal antibody.

47. Method for determining regression, progression or onset of a condition characterized by abnormal levels of a protein encoded by a nucleic acid molecule comprising a nucleotide sequence set forth in SEQ ID NO: 1, 2, 3, 4 or 5, comprising monitoring a

sample from a patient with said condition for a parameter selected from the group consisting of (i) protein, (ii) a peptide derived from said protein and (iii) cytolytic T cells specific for a peptide derived from said protein and an MHC molecule to which is bound is indicative of progression or regression or onset of said condition.

48. The method of claim 47, wherein said sample is a body fluid or effusion.

49. The method of claim 47, wherein said sample is a tissue.

50. The method of claim 47, wherein contacting said sample with an antibody which specifically binds with said protein or peptide.

51. The method of claim 50, wherein said antibody is labelled with a radioactive label or an enzyme.

52. The method of claim 50, wherein said antibody is a monoclonal antibody.

53. The method of claim 47, comprising amplifying RNA which codes for said protein.

54. The method of claim 53, wherein said amplifying comprises carrying out polymerase chain reaction.

55. The method of claim 47, comprising contacting said sample with a nucleic acid molecule which specifically hybridizes to a nucleic acid molecule which codes for or expresses said SCP protein.

56. The method of claim 47, comprising assaying said sample for said peptide.

**Abstract Of The Disclosure**

Various molecules associated with disorders such as colon cancer are disclosed. The invention also discloses diagnostic and therapeutic methods based upon these molecules.

LUD 5506-JEL/NDK

Express Mail Label No:  
EL024661754US  
Date of Deposit: 2-11-00

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, the specification of which

( ) is attached hereto.

(X) was filed on October 10, 1997 as Application Serial No. CS/948,701, and was amended on (1) \_\_\_\_\_, (2) \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

Priority Claimed

(Number)	(Country)	(Day/Month/Year Filed)	Yes ( )	No ( )
----------	-----------	------------------------	---------	--------

(Number)	(Country)	(Day/Month/Year Filed)	Yes ( )	No ( )
----------	-----------	------------------------	---------	--------

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
----------------------	---------------	-------------------------------------

(Applic. Serial No.)	(Filing Date)	(Status-patented/pending/abandoned)
----------------------	---------------	-------------------------------------

LUD 5506-JEL/NDR

Power of Attorney

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Norman D. Hanson, Reg. No. 30,946; Andrew L. Tiajoloff, Reg. No. 31,575; John A. Bauer, Reg. No. 32,554; Mary Anne Schofield, Reg. No. 36,669; Madeline F. Baer, Reg. No. 36,437 and James R. Crawford, Reg. No. 39,155, my attorneys with full power of substitution and revocation. Address all telephone calls to Norman D. Hanson, at (212) 688-9200. Address all correspondence to:

FELFE & LYNCH  
805 Third Avenue  
New York, New York 10022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) <u>Matthew J. Scanlan</u> Full Name/Sole or First Inventor	<u>Signature</u>	<u>Date</u>
Residence: <u>1275 York Avenue</u> <u>New York, New York 10021</u>	<u>U.S.A.</u>	<u>Citizenship</u>
Post Office Address: <u>Memorial Sloan-Kettering Cancer Center</u> <u>1275 York Avenue, New York, New York 10021</u>		
(2) <u>Yao-Tseng Chen</u> Full Name/Second Inventor	<u>Yao-Tseng Chen</u> <u>Signature</u>	<u>2/3/58</u> <u>Date</u>
Residence: <u>525 East 68th Street</u> <u>New York, New York 10021</u>	<u>Taiwan</u> <u>Citizenship</u>	
Post Office Address: <u>525 East 68th Street</u> <u>New York, New York 10021</u>		

DECLARATION FOR PATENT APPLICATION

As a below named inventor, I hereby declare that:

My resident, post office address and citizenship are as stated below next to my name.

I believe I am the original, first and sole inventor (if only one name is listed below) or an original, first and joint inventor (if plural names are listed below) of the subject matter which is claimed and for which a patent is sought on the invention entitled ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND TREATING COLON CANCER, the specification of which

( ) is attached hereto.

(X) was filed on October 10, 1997 as Application Serial No. 08/948,705 and was amended on (1) \_\_\_\_\_, (2) \_\_\_\_\_ (if applicable).

I hereby state that I have reviewed and understand the contents of the above identified specification, including the claims, as amended by any amendment referred to above.

I acknowledge the duty to disclose information which is material to the examination of this application in accordance with Title 37, Code of Federal Regulations, 1.56(a).

Foreign Priority Applications

I hereby claim foreign priority benefits under Title 35, United States Code §119 of any foreign application(s) for patent or inventor's certificate listed below and have also identified below any foreign application for patent or inventor's certificate having a filing date before that of the application on which priority is claimed:

			<u>Priority Claimed</u>
<u>(Number)</u>	<u>(Country)</u>	<u>(Day/Month/Year Filed)</u>	Yes ( ) No ( )
_____	_____	_____	Yes ( ) No ( )
_____	_____	_____	Yes ( ) No ( )

U.S. Priority Applications

I hereby claim the benefit under Title 35, United States Code, §120 of any United States application(s) listed below and, insofar as the subject matter of each of the claims of this application is not disclosed in the prior United States application in the manner provided by the first paragraph of Title 35, United States Code, §112, I acknowledge the duty to disclose material information as defined in Title 37, Code of Federal Regulations, §1.56(a) which occurred between the filing date of the prior application and the national or PCT international filing date of this application:

<u>(Applic. Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status-patented/pending/abandoned)</u>
-----------------------------	----------------------	--

<u>(Applic. Serial No.)</u>	<u>(Filing Date)</u>	<u>(Status-patented/pending/abandoned)</u>
-----------------------------	----------------------	--

Power of Attorney

I hereby appoint the following attorneys to prosecute this application and transact all business in the Patent and Trademark Office connected therewith: John E. Lynch, Reg. No. 20,940; Peter F. Felfe, Reg. No. 20,297; Norman D. Hanson, Reg. No. 30,946; Andrew L. Tiajoloff, Reg. No. 31,575; John A. Bauer, Reg. No. 32,554; Mary Anne Schofield, Reg. No. 36,669; Madeline F. Baer, Reg. No. 36,437 and James R. Crawford, Reg. No. 39,155, my attorneys with full power of substitution and revocation. Address all telephone calls to Norman D. Hanson, at (212) 688-9200. Address all correspondence to:

FELFE & LYNCH  
805 Third Avenue  
New York, New York 10022

I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under Section 1001 of Title 18 of the United States Code and that such willful false statements may jeopardize the validity of the application or any patent issued thereon.

(1) Matthew J. Scanlan  
Full Name/Sole or First Inventor

*Matthew Scanlan*  
Signature

JANUARY 14, 1978  
Date

Residence: 1275 York Avenue  
New York, New York 10021

U.S.A.  
Citizenship

Post Office Address: Memorial Sloan-Kettering Cancer Center  
1275 York Avenue, New York, New York 10021

(2) Yao-Tseng Chen  
Full Name/Second Inventor

Signature

Date

Residence: 525 East 68th Street  
New York, New York 10021

Taiwan  
Citizenship

Post Office Address: 525 East 68th Street  
New York, New York 10021

(3) Elisabeth Stockert  
Full Name/Third Inventor

Signature

JANUARY 14, 1998

Date

Residence: 1275 York Avenue  
New York, New York 10021

AUSTRIA U.S.A.

Citizenship

Post Office Address: Memorial Sloan-Kettering Cancer Center  
1275 York Avenue, New York, New York 10021

(4) Lloyd J. Old  
Full Name/Fourth Inventor

Signature

Date

Residence: 1345 Avenue of the Americas  
New York, New York 10105

U.S.A.

Citizenship

Post Office Address: 1345 Avenue of the Americas  
New York, New York 10105

Express Mail Label No:

EL024661754US

Date of Deposit: 2-11-00

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants: Scanlan et al.  
 Serial No.: 08/948,705  
 Filed: October 10, 1997  
 For: ISOLATED NUCLEIC ACID MOLECULES ASSOCIATED WITH  
 COLON CANCER AND METHODS FOR DIAGNOSING AND  
 TREATING COLON CANCER  
 Examiner: J.S. Brusca  
 Art Unit: 1636

Assistant Commissioner for Patents  
 Washington, D.C. 20231

ASSOCIATE POWER OF ATTORNEY

Sir:

The undersigned attorney has the power of attorney in the above-identified United States patent application, and hereby grants an associate power in the application to:

David Wolf	17,528	James H. Morris	34,681	John R. Van Amsterdam	40,212
George L. Greenfield	17,755	Peter C. Lando	34,654	Matthew B. Lowrie	38,228
Stanley Sacks	19,800	Gary S. Engelson	35,128	Michael G. Verga	39,410
Edward F. Perlman	28,105	Peter J. Gordon	35,164	Robert E. Rigby, Jr.	36,904
Lawrence M. Graen	29,384	Randy J. Prittsker	35,985	Robert A. Skrivanek, Jr.	41,316
Steven J. Henry	27,900	Richard F. Giunta	36,149	Robert M. Abrahamson	40,886
Therese A. Hendricks	30,389	Douglas R. Wolf	36,971	Lesley A. Hamlin	41,054
Edward R. Gates	31,616	Elizabeth R. Plumer	36,637	Lindsay G. McGuinness	38,549
William R. McClellan	29,409	Timothy J. Oyer	36,628	Mike W. Crosby	40,970
Ronald J. Krenzendorf	20,004	John N. Anastasi	37,765	Ivan D. Zitkovsky	37,482
M. Lawrence Oliveria	30,915	HeLEN C. Kindregan	39,248	Michele J. Young	P-43,299
James J. Foster	30,052	James M. Hanifin, Jr.	39,213	Edward J. Russavage	P-43,069
Charles E. Pfund	17,030	Christopher S. Schultz	37,929	Alan B. Shezz	P-42,147
Jason M. Honeyman	31,624	Paul D. Sorkin	39,039		

all of:

Wolf, Greenfield & Sacks, P.C.,  
 Federal Reserve Plaza  
 600 Atlantic Avenue  
 Boston, MA 02210-2211

Respectfully submitted,

FULBRIGHT &amp; JAWORSKI, L.L.P.

By: Norman D. Hanson  
 Norman D. Hanson  
 Reg. No. 30,946

805 Third Avenue  
 New York, New York 10022  
 (212) 688-9200  
 Dated: July 13, 1998

\*\* TOTAL PAGE.03 \*\*

SEQUENCE LISTING

5           <110> Scanlan, Matthew J.  
              Chen, Yao-Tseng  
              Stockert, Elisabeth  
              Old, Lloyd J.

10          <120> ISOLATED NUCLEIC ACID MOLECULES  
              ASSOCIATED WITH COLON CANCER AND METHODS FOR DIAGNOSING AND  
              TREATING COLON CANCER

<130> LUD-5506-JEL/NDH

15          <140> US 08/948,705  
              <141> 1997-10-10

<160> 8

20          <170> FastSEQ for Windows Version 3.0

25          <210> 1  
              <211> 1552  
              <212> DNA  
              <213> Homo Sapiens

<400> 1

cttctggatg	catccgagaa	gctaaaactt	acttatgagg	aaaagtgtga	aattgagggaa	60
tcccaattga	agtttttgag	gaacgactta	gctgaatato	agagaacttg	tgaagatctt	120
aaagagcaac	taaagcataa	agaatttctt	ctggctgcta	atacttgtaa	ccgtgttgt	180
ggctttgtt	tgaaatgtgc	tcagcatgaa	gctgttcttt	cccaaaccctt	tactaatgtt	240
catatgcaga	ccatcgaaag	actggttaaa	gaaagagatg	acttgatgtc	tgcacttagtt	300
tccgtaagga	gcagcttggc	agatacgcag	caaagagaag	caagtgttta	tgaacaggtg	360
aaacaagttt	tgcaaataatc	tgaggaagcc	aattttgaaa	aaaccaaggc	tttaatccag	420
tgtgaccagt	tgaggaagga	gctggagagg	caggcggagc	gacttgaaaa	agaacttgc	480
tctcagcaag	agaaaaaggc	cattgagaaa	gacatgtga	aaaaggaaat	aacgaaaagaa	540
agggagtaca	tgggatcaaa	gatgttgc	ttgtctcaga	atattgc	actggaggcc	600
caggtggaaa	aggttacaaa	ggaaaagatt	tcaagtatta	atcaacttgg	ggaaattcaa	660
agccagctgg	tttctcgaaa	aatggatgtc	acaaagggt	gtggagaaat	gcgcstatcag	720
40          ctgaataaaaa	ccaacatgga	gaaggatgag	gcagaaaaagg	agcaca	jaga	780
aaaactaaca	gggatcttga	aattaaagat	cagggaaatag	agaaat	ttag	840
gatgaaagca	aacaacactt	ggaacaggag	cagcagaagg	cagccctggc	cagagaggag	900
tgcctgagac	taacagaact	gctgggcgaa	tctgagcacc	aactgcac	caccatct	960
45          gaaatagctc	aactcagtca	agaaaaaagg	tatacatatg	ataaattggg	aaagttacag	1020
agaagaaatg	aagaatttgg	ggaacagtgt	gtccagcatg	ggagagtaca	tgagacgtg	1080

	aagcaaaggc taaggcagct ggataagcac agccaggcca cagcccagca gctggtgca ctcctcagca agcagaacca gcttctcctg gagaggcaga gcctgtcgga agaggtggac cggctcgcca cccagttacc cagcatgcc caatctgatt gctgacctgg atgaaacaga gtgaaataaa tgaattacaa agagatattt acattcatct ggtagact taatatgcc 5 caacgcacca cgacacctcc agggtgacac cgccctcagcc tgcagtgggg ctggtcctca tcaacgcggg cgctgtcccc gcacgcagtc gggctggagc tggagtctga ctctagctga gcagactcct ggtgtatgtt ttcaaaaatg gcttgaagtt atgtgtttaa atctgtcat tcgtatgcta gttatacat atgatttca ataaatgaac ttttaaaga aa	1140 1200 1260 1320 1380 1440 1500 1552
10	<210> 2 <211> 2885 <212> DNA <213> Homo Sapiens	
15	<400> 2 ggaattcctc ttgtcgaagt caaaggagcc cacaccaggc ggcctcaacc attccctccc acagcaccggc aaatgctggg gagccacca tgottctttg gaccagagtt cccctccca gagcggccccc cctgggacgc ctccctccta caaactgcct ttgcctgggc cctacgacag tcgagacgac ttcccccctcc gcaaaaacagc ctgtacccccc aacttggaaag tgcgttcaag gttaaaacag aagggtggctg agcggagaag cagtccctc ctgcgtcgca aggatggac tgttattagc acctttaaga agagagctgt tgagatcaca ggtgcggggc ctggggcgtc gtccgtgtgt aacagcgcac ccggctccgg ccccgactct cccaacagct cccacagcac catcgcttag aatggcttta ctggctcagt ccccaacatc cccactgaga tgctccctca gcaccggagcc ctccctctgg acagctcccc caaccagttc agcctctaca cgtctccctc tctgcccac atctccctag ggctgcaggc cacggtaact gtcaccaact cacacctcac tgccctcccc aagctgtcga cacagcagga ggccgagagg caggccctcc agtccctg gcagggtggc acgctgaccg gcaagttcat gagcacatcc tctattcttg gtcacccctg gggcgtggca ctggaggggcg acgggagccc ccacggcat gcctccctgc tgcagcatgt gtctgtgtgt gacggccc ggcacggcag caccctcatt gctgtgccac tccacggca gtccccacta gtgacgggtg aacgtgtggc caccacatg cggacggtag gcaagctccc gcggcatogg cccctgagcc gcactcagtc ctacccgctg ccgcagagtc cccaggccct gcagcagctg gtcacccatc aacagcacca gcagttcttg gagaagcaga agcagcagca gtacagctg ggcaagatcc tcaccaagac agggggactg cccaggcagc ccaccaccca ccctgaggag acagaggagg agctgacgga gcacggcaggat gtcttgctgg gggaggag 35 cctgaccatg ccccgaggc gctccacaga gagtgagagc acacaggaag acctggagga ggaggacgag gaagaggatg gggaggagga ggaggattgc atccaggttta aggacgagga ggcggagagt ggtgtgtgg agggggccga cttggaggag cttgggtctg gataaaaaaa actgttctca gatgcccac cgctgcaacc ttgcaggatg taccaacgc ccctcagc ggccactgtg cccaccaag ccctggcccg taccaatcc tccctgctg cccctgggg 40 catgaagaac cccccagacc aacccgtcaa gcaccccttc accacaagtg tggtctac cacgttcatg ctaaagcacc agtgcacgtg cggaaacaca cacgtgcacc ctgagcatgc tggccggatc cagacatct ggtcccgct gcaggagaca ggcctgctt gcaagtgc gcggatccga ggtcgcaaag ccacgctaga tgagatccag acagtgcact ctgaatacca caccctgctc tatggacca gtccctcaa ccggcagaag ctagacagca agaagttgt 45 cggcccattc agccagaaga tgtatgtgt gtcacccatcg gggggcatcg ggggtggacag	60 120 180 240 300 360 420 480 540 600 660 720 780 840 900 960 1020 1080 1140 1200 1260 1320 1380 1440 1500 1560 1620 1680 1740 1800

tgacaccgtg tggaatgaga tgcactcctc cagtgcgtg cgcatggcag tgggctgact 1860  
gctggagctg gccttcaagg tggctgcagg agagctcaag aatggatttgc ccatcatccg 1920  
gccccccagga caccacgccc aggaatccac agccatggga ttctgcttc tcaactctgt 1980  
agccatcacc gcaaaactcc tacagcagaa gttgaacgtg ggcaagggtcc tcatacggtgaa 2040  
5 ctgggacatt caccatggca atggcaccca gcaggcggttacaatgacc cctctgtgct 2100  
ctacatctct ctgcacatcgat atgacaacgg gaacctctt ccaggctctg gggctcctga 2160  
agagggttgtt ggaggaccag gcgtgggta caatgtgaac gtggcatggaa caggagggtgt 2220  
ggaccccccatttggagacg tggagtacact tacagccttc aggacagtgg tggatggccat 2280  
tgcccacgag ttctcacctg atgtggcctt agtctccgccc gggtttgatg ctgttgaagg 2340  
10 acatctgtct cctctgggtg gctactctgt caccgcacaga tggtttggcc acttgaccag 2400  
gcagctgatg accctggcag gggggccgggt ggtgctggcc ctggaggagg gccatgactt 2460  
gaccgcacatc tgtgtatgcct ctgaagcttgc tggctcggct ctgctcagtg taaagctgca 2520  
gcccttggat gaggcagtct tgcagcaaaa gcccaacatc aacgcagtgg ccacgctaga 2580  
15 gaaagtcatc gagatccaga gcaaacaactg gagctgtgtg cagaagttcg ccgctggct 2640  
ggggccgggtcc ctgcgaggggg cccaaaggcagg tgagaccgaa gaagccgaaa tgtgaacgcc 2700  
atggccttgc tgggtgggg ggccgaacag gcccaagctg cggcagcccg ggaacacacgc 2760  
cccaggccgg cagaggagcc catggagcag gagcctgccc tgtgacgccc cggcccccattt 2820  
cccttgggc ttaccatttgc tggatggat tattttttct attaaaaaca aaaagttaaa 2880  
aattt 2885

20 <210> 3  
<211> 1298  
<212> DNA  
<213> Homo Sapiens

25 <220>  
<221> unsure  
<222> 55..55  
<223>

30 <220>  
<221> unsure  
<222> 141..141  
<223>

35 <220>  
<221> unsure  
<222> 199..99  
<223>

40 <220>  
<221> unsure  
<222> 342..342  
<223>

<220>  
<221> unsure  
<222> 352..352  
<223>

5

<220>  
<221> unsure  
<222> 722..722  
<223>

10

<220>  
<221> unsure  
<222> 750..750  
<223>

15

<220>  
<221> unsure  
<222> 1058..1058  
<223>

20

<220>  
<221> unsure  
<222> 1101..1101  
<223>

25

<220>  
<221> unsure  
<222> 1144..1144  
<223>

30

<400> 3

ggctgctgaa atgactgcga accggcttgc agagagcctt ctggcttga gccancaggaa	60
agaactagcg gattgccaa aagactacct cttgagttagt agtgaagatg agggggacaa	120
tgtggagag agaaagcatc naaagcttct ggaagcaatc agttcccttg atggaaagaa	180
taggcggaaa ttggctgana ggtctgaggc tagtctgaag gtgtcagagt tcaatgtcag	240
ttctgaagga tcaggagaaaa agctggctt tgcatctg cttgagcctg ttaaaacttc	300
atcttctttg gccactgtga aaaagcaact gagtagatgc anatcaaaga anacagtgga	360
gttacctctg aacaaagaag agattgaacg gatccacaga gaatagcatt caataaaacg	420
cacaagtcct ctccaaatgg gaccctgtcg tcctgaagaa ccggcaggca gagcagctgg	480
tttttcccct ggagaaaagag gagccagcca ttgctcccat tgaacatgtg ctcagtggct	540
ggaaggcaag aactcccctg gagcaggaaa ttttcaacct cctccataag aacaaggcagc	600
cagtgacaga cccttactg acccctgtgg aaaaggcctc tctccgagcc atgagcctag	660
aagaggcaaa gatgcgacga gcagagcttc agaggcctcg ggctctgcag tcctactatg	720

	angccaaggc tcgaagagag aagaaaatcn aaagttaaaa gtatcacaaa gtcgtgaaga	780
	aaggaaaggc caagaaagcc ctaaaagagt ttgagcagct gcggaagggtt aatccagctg	840
	ccgcactaga agaacgaaga aaagagggaaa gaaggaggag gagaaagaag aagaacaagg	900
	agaagaagaa agaagaaggg agaaggagaa gaaaagaagg agaagaggaa aaggaagaag	960
5	gagaaagaaa aggagaagga aaagaaaaag aaggagaaga aagaagaact aagaagaagg	1020
	agaggaagaa taagaaggaa agaagaaaga aaaaagtnaa agaagaagaa agaaggaaga	1080
	agggaaagaag aggaagaact nagaagaaga aagaggagga aagaagaaaag aagaataagg	1140
	aacnagaaag aaggagaaga aagaataaga agaggaagaa gaaaaagaag aaaagaagaa	1200
10	ggaaagaagg agaaaaagg aagaagaaag tagaaagcgg aagaaagaaa	1260
	agaaaagtata agaaggaaga agaagaaaga agaaaaaa	1298

<210> 4

<211> 2236

<212> DNA

15       <213> Homo Sapiens

<400> 4

	cctggcccg tcgcggcgc ggctcttcc agtcctggc agccggcac ccgaaggaac	60
	gggtcgtgca acgacgcagc tggacctggc ccagccatgg accgaaaagt gcccccggaa	120
	ttccggcata aggtggattt tctgatttgc aatgtatgcag agaaggacta tctctatgtat	180
	gtgctgcgaa tgtaccacca gaccatggac gtggccgtgc tcgtggaga cctgaagctg	240
	gtcatcaatg aaccaggccg tctgcctctg ttttatgcca ttcggccgct gatcccactg	300
	aagcaccagg tggatatatga tcagctgacc ccccgccgct ccaggaagct gaaggaggtg	360
	cgtctggacc gtctgcaccc cgaaggccctc ggcctgagtg tgctgggtgg cctggagttt	420
20	ggctgtgggc tcttcatctc ccacctcatc aaaggcggtc aggcagacag cgtcgggctc	480
	caggttaggg acgagatcgt ccggatcaat ggatattcca tctcctcctg taccatgag	540
	gaggtcatca acctcattcg aaccaagaaa actgtgtcca tcaaagttag acacatcgcc	600
	ctgatccccg tgaaaagctc tcctgatgag cccctcaattt ggcagtatgt ggatcagttt	660
	gtgtcgaaat ctggggcgt gogaggcagc ctgggctccc ctggaaatcg gaaaaacaag	720
25	gagaagaagg tcttcatcag cctggtaggc tcccgaggcc ttggctgcag catttccagc	780
	ggcccccattcc agaagcctgg catcttatac agccatgtga aacctggctc cctgtctgct	840
	gaggtggat tggagatagg ggaccagatt gtgcgaagtca atggcgtcga cttctctaacc	900
	ctggatcaca aggaggctgt aaatgtgctg aaaaatagcc gcagcctgac catctccatt	960
	gtagctgcag ctggccggga gctgttcatg acagaccggg agcggctggc agaggcgcgg	1020
30	cagcgtgagc tgcaagcggca ggagcttctc atgcagaagc ggctggcgtt ggagtccaaac	1080
	aagatcctcc aggagcagca ggagatggag cggcaaaggaa gaaaagaaat tgcccagaag	1140
	gcagcagagg aaaaatgagag ataccggaaag gagatggaaac agattgtaga ggaggaagag	1200
	aagttttaaga agcaatggga agaagactgg ggtcaaaagg aacagctact cttgcctaaa	1260
	accatcactg ctgaggtaca cccagttaccc cttcgcaagc caaatgtatga tcagggagtg	1320
35	gaacctgagc tcgagccgc agatgacctg gatggaggca cggaggagca gggagagcag	1380
	gatttccgga aatatgagga aggcttgc acctactcta tggtcaccctt agagcagatc	1440
	atggggaaagg atgtccggct cctacgcac aagaaggagg gatcctttaga cttggccctg	1500
40	gaaggcgggtg tggactcccc cattggaaag gtggctgttt ctgctgtgtt tgagcgggga	1560

gctgctgagc	ggcatggtgg	cattgtgaaa	ggggacgaga	tcatggcaat	caacggcaag	1620
attgtgacag	actacaccct	ggctgaggct	gacgctgccc	tgcagaaggc	ctggaatcag	1680
ggcgggact	ggatcgacct	tgtggttgcc	gtctgcccc	caaaggagta	tgacgatgag	1740
5	ctgacccct	tgctgaagtc	caaaaagggaa	aaccaaattc	acgcgttagg	1800
ctccggcccc	acctcgtaa	cacaaggcct	cggaccagcc	ttgagagagg	ccacatgaca	1860
cacaccagat	ggcatccttg	ggacctgaat	ctatcaccca	ggaatctcaa	actccctttg	1920
gccctgaacc	agggccagat	aaggaacagc	tcgggccact	ttttgaagg	ccaatgtgga	1980
ggaaaggag	cagccagccg	tttggagaa	gatctcaagg	atccagactc	tcattcctt	2040
cctctggccc	agtgaatttg	gtctctccca	gcttggggg	actccttct	tgaaccctaa	2100
10	taagacccca	ctggagtctc	tctctctcca	tccctctct	ctgcctctg	2160
tgccaggatt	gtcactccaa	accttactct	gagtcattta	ataaaataaa	cagattttt	2220
ttccagctta	aaaaaa					2236

<210> 5

15 <211> 2162

<212> DNA

<213> Homo Sapiens

<400> 5

cctggcccg	tcgcggtcgc	ggctcttcc	agtcctggc	agccggcac	ccgaaggAAC	60
gggtcggtca	acgacgcgc	tggacctggc	ccagccatgg	accgaaaagt	ggcccgagaa	120
ttccggcata	agggtggattt	tctgattgaa	aatgatgcag	agaaggacta	tctctatgtat	180
gtgctgcgaa	tgtaccacca	gaccatggac	gtggccgtgc	tctgtggaga	cctgaagctg	240
gtcatcaatg	aaccaggccg	tctgcctctg	ttttagtgcct	ttcggccgt	gatcccactg	300
aagcaccagg	tggaatatga	tcagctgacc	ccccggcgct	ccaggaagct	gaaggaggtg	360
cgtctggacc	gtctgcaccc	cgaaggcctc	ggcctgagtg	tgcgtggtgg	cctggagtt	420
ggctgtggc	tcttcatctc	ccacctcatc	aaaggcgtc	aggcagacag	cgtcggcgtc	480
caggtagggg	acgagatcgt	ccggatcaat	ggatattcca	tctcctcctg	tacccatgag	540
gaggtcatca	acctcattcg	aaccaagaaa	actgtgtcca	tcaaagttag	acacatcgcc	600
30 ctgatcccc	tgaaaagctc	tcctgtatgag	ccctcactt	ggcagtatgt	ggatcagtt	660
gtgtcgaaat	ctggggcggt	gcgaggcagc	ctgggctccc	ctggaaatcg	ggaaaacaag	720
gagaagaagg	tcttcatcag	cctggtaggc	tcccgaggcc	ttggctgcag	catttccac	780
ggccccatcc	agaaggctgg	catcttatac	agccatgtga	aacctggctc	cctgtctgt	840
35 gaggtggat	tggagatagg	ggaccagatt	gtcgaagtca	atggcgtcga	tttctctaacc	900
ctggatcaca	aggaggctgt	aaatgtgtc	aaaaatagcc	gcagcctgac	catctccatt	960
gtagctgcag	ctggccggga	gctgttcatg	acagaccggg	agcggctggc	agaggcgcgg	1020
cagcgtgagc	tgcagcggca	ggagcttctc	atgcagaaggc	ggctggcgat	ggagtccaaac	1080
40 aagatcctcc	aggagcagca	ggagatggag	cggcaaaggaa	aaaaagaaaat	tgcccagaag	1140
gcagcagagg	aaaatgagag	ataccggaaag	gagatggaaac	agattgtaga	ggaggaagag	1200
aagtttaaga	agcaatggga	agaagactgg	ggctcaaagg	aacagctact	tttgcctaaa	1260
accatcactg	ctgaggtaca	cccagtaccc	cttcgcaagc	caaagtgatt	tccggaaataa	1320
tgaggaaggc	tttggaccct	actctatgtt	cacccagag	cagatcatgg	ggaaggatgt	1380
ccggctccct	cgcatcaaga	aggaggatc	cttagacctg	gccctggaag	gcgggtgtgga	1440

	ctcccccatt gggaaagggtgg tcgtttctgc ttgttatgag cggggagctg ctgagcggca	1500
	tggtggcatt gtgaaagggg acgagatcat ggcaatcaac ggcaagattg tgacagacta	1560
	caccctggct gaggctgacg ctgccctgca gaaggcctgg aatcagggcg gggactggat	1620
	cgaccttgtg gttccgtct gccccccaaa ggagtatgac gatgagctga cttcttgct	1680
5	gaagtccaaa agggaaacc aaattcacgc gtttaggaaac agttagctcc ggccccacac	1740
	cgtgaacaca aagcctcgga ccagccttga gagaggccac atgacacacaca ccagatggca	1800
	tccttgggac ctgaatctat cacccagggaa tctcaaactc cctttggccc tgaaccagg	1860
	ccagataagg aacagctcg gccactttt tgaaggccaa tgtggaggaa agggagcagc	1920
	cagccgtttg ggagaagatc tcaaggatcc agactctcat tcccttcctc tggcccagt	1980
10	aatttggct ctccagctt tgggggactc cttccttga ccctaataag acccccactgg	2040
	agtctctctc tctccatccc tctcctctgc cctctgctct aattgctgcc aggattgtca	2100
	ctccaaacct tactctgagc tcattaataa aataaacaga tttatcc agctaaaaaa	2160
	aa	2162
15	<210> 6	
	<211> 1789	
	<212> DNA	
	<213> Homo Sapiens	
20	<400> 6	
	cttctggatg catccgagaa gctaaaactt acttatgagg aaaagtgtga aattgaggaa	60
	tcccaattga agttttttagt gaacgactta gctgaatatc agagaacttg tgaagatctt	120
	aaagagcaac taaagcataa agaatttttctt ctggctgcta atacttgtaa ccgtgttgg	180
	ggtctttgtt taaaatgtgc tcagcatgaa gctgttcttt cccaaaccca tactaatgtt	240
25	catatgcaga ccatcgaaag actggtaaaa gaaagagatg acttgatgtc tgcactagtt	300
	tccgttaaggaa gcagcttggc agatacgcag caaagagaag caagtgttta tgaacaggt	360
	aaacaagttt tgcaaatatc tgaggaagcc aattttgaaa aaaccaaggc ttaatccag	420
	tgtgaccagt tgaggaagga gctggagagg caggcggagc gacttgaaaa agaacttgca	480
	tctcagcaag agaaaaaggc cattgagaaa gacatgtga aaaagaaaaat aacgaaagaa	540
30	agggagtaca tggatcaaa gatgttgc tttgtctcaga atattgccc actggaggcc	600
	caggtggaaa aggttacaaa ggaaaagatt tcagcttta atcaacttggaa gaaaatttca	660
	agccagctgg cttctcgaaa aatggatgtc acaaagggtgt gtggagaaaat ggcgtatcag	720
	ctgaataaaaa ccaacatggaa gaaggatgag gcagaaaagg agcacagaga gttcagagca	780
	aaaactaaca gggatcttga aattaaagat cagggaaatag agaaaatttgg aatagaactg	840
35	gatgaaagca aacaacactt ggaacaggag cagcagaagg cagccctggc cagagaggag	900
	tgcctgagac taacagaact gctggcgaa tctgagcacc aactgcaccc caccagacag	960
	gaaaaagata gcattcagca gagcttttagc aaggaagcaa aggcccaagc cttcaggcc	1020
	cagcaaagag agcaggagct gacacagaag atacagcaaa tggaaagccc gcatgacaaa	1080
	actgaaaatg aacagtattt gttgctgacc tcccagaata catttttgc aagttaaag	1140
40	gaagaatgt gtacattagc caagaaactg gaacaaatct ctcaaaaaac cagatctgaa	1200
	atagctcaac tcagtcaaga aaaaaggat acatatgata aattggggaaa gttacagaga	1260
	agaaatgaag aattggagga acagtgtgtc cagcatgggaa gactacatga gacgatgaag	1320
	caaaggctaa ggcagctgga taagcacagc caggccacag cccagcagct ggtcagctc	1380

ctcagcaagc agaaccagct tctcctggag aggcagagcc tgtcggaaga ggtggaccgg	1440
ctgcggaccc agttacccag catgccacaa tctgattgct gacctggatg gaacagagtg	1500
aaataaaatga attacaaaga gatatttaca ttcatctggt ttagacttaa tatgccacaa	1560
cgcaccacga ccttcccagg gtgacaccgc ctcagcctgc agtggggctg gtcctcatca	1620
5 acgcgggcgc tgtccccgca cgca gtcggg ctggagctgg agtctgactc tagctgagca	1680
gactccttgtt gatatgtttc agaaatggct tgaagttatg tgtttaaattc tgctcattcg	1740
tatgcttagt tatacatatg atttcaata aatgaacttt ttaaaagaaa	1789

<210> 7

10 <211> 1306

<212> DNA

<213> Homo Sapiens

<400> 7

15 aaaaatagcc gcagcctgac catctccatt gtagctgcag ctggccggga gctgttcatg	60
acagaccggg agcggctggc agaggcgcgg cagcgtgagc tgcagcggca ggagcttctc	120
atgcagaagc ggctggcgat ggagtccaaac aagatcctcc aggagcagca ggagatggag	180
cgccaaagga gaaaagaaat tgcccagaag gcagcagagg aaaaatgagag ataccggaag	240
gagatggaac agattgtaga ggaggaagag aagttttaaga agcaatggga agaagactgg	300
20 ggctcaaagg aacagctact cttgcctaaa accatcaactg ctgaggtaca cccagtagcc	360
cttcgcaagc caaagtatga tcagggagtg gaacctgagc tcgagccgc agatgacctg	420
gatggaggca cggaggagca gggagagcag gatttccgga aatatgagga aggcttgac	480
ccctactcta tgttcacccc agagcagatc atggggagg atgtcggct cctacgcac	540
aagaaggagg gatcattaga cctggccctg gaaggcggtg tggactcccc cattgggaag	600
25 gtggcgttt ctgctgtgt a tgagcgggga gctgctgagc ggcattgtgg cattgtgaaa	660
ggggacgaga tcatggcaat caacggcaag attgtgacag actacaccct ggctgaggct	720
gacgctgccc tgcagaaggc ctggaatcag ggcggggact ggatcgacct tgggttgcc	780
gtctgccccca caaaggagta tgacgatgag ctgaccttct tgctgaagtc caaaaggggaa	840
aaccaaattc acgcgtttagg aaacagttag cttccggccccc acctcgtgaa cacaaaggct	900
30 cggaccagcc ttgagagagg ccacatgaca cacaccatg ggcattccttg ggacctgaat	960
ctatcaccctt ggaatctcaa actcccttt gccctgaacc agggccagat aaggaacacgc	1020
tcggggccact ttttgaagg ccaatgtgga gggaaaggagg cagccagccg tttggggagaa	1080
gatctcaagg atccagactc tcattcctt cctctggccc agtgaatttg gtctctccca	1140
gctttggggg actccttcct tgaaccctaa taagacccca ctggagtctc tctctctcca	1200
35 tccctctact ctgcctctg ctctaattgc tgccaggatt gtcactccaa accttactct	1260
gagctcattha ataaaataaa cagatttatt ttccagctta aaaaaaa	1306

<210> 8

40 <211> 2289

<212> DNA

<213> Homo Sapiens

<400> 8

	cctggcccg	tcgcggtcgc	ggctcttcc	agctcctggc	agccggcac	ccgaaggaac	60
	gggtcgta	acgacgcgc	tggacctggc	ccagccatgg	accgaaaagt	gccccgagaa	120
	ttccggata	aggtgtatt	tctgattgaa	aatgatgcag	agaaggacta	tctctatgat	180
	gtgctgcga	tgtaccacca	gaccatggac	gtggccgtgc	tcgtgggaga	cctgaagctg	240
5	gtcatcaatg	aaccagccg	tctgcctctg	tttgatgcca	ttcggccgt	gatcccactg	300
	aagcaccagg	tggaatatga	tcagctgacc	ccccggcgct	ccaggaagct	gaaggaggtg	360
	cgtctggacc	gtctgcaccc	cgaaggcctc	ggcctgagtg	tgcgtggtgg	cctggagtt	420
	ggctgtggc	tcttcatctc	ccacctcatc	aaaggcggtc	aggcagacag	cgtcgggctc	480
10	caggtagggg	acgagatcgt	ccggatcaat	ggatattcca	tctcctcctg	tacccatgag	540
	gaggtcatca	acctcattcg	aaccaagaaa	actgtgtcca	tcaaagttag	acacatcgcc	600
	ctgatcccc	tgaaaagctc	tcctgatgag	cccccactt	ggcagtatgt	ggatcagtt	660
	gtgtcgaaat	ctggggcggt	gcgaggcagc	ctgggctccc	ctggaaatcg	gaaaaacaag	720
	gagaagaagg	tcttcatcag	cctggtaggc	tcccggaggcc	ttggctgcag	catttccagc	780
15	ggccccatcc	agaagcctgg	catcttatac	agccatgtga	aacctggctc	cctgtctgct	840
	gaggtggat	tggagatagg	ggaccagatt	gtcgaagtca	atggcgtcga	cttctcta	900
	ctggatcaca	aggaggctgt	aaatgtgctg	aaaaatagcc	gcagcctgac	catctccatt	960
	gtagctgcag	ctggccggga	gctgttcatg	acagaccggg	agcggctggc	agaggcgcgg	1020
	cacgtgagc	tgcagcggca	ggagcttctc	atgcagaagc	ggctggcgat	ggagtccaac	1080
20	aagatcctcc	aggagcagca	ggagatggag	cggcaaagga	gaaaagaaat	tgcccagaag	1140
	gcagcagagg	aaaatgagag	ataccggaag	gagatggAAC	agattgtaga	ggaggaagag	1200
	aagtttAAGA	agcaatggga	agaagactgg	ggctcaaagg	aacagctact	cttgcctaaa	1260
	accatcactg	ctgaggtaca	cccagtaccc	cttcgcaagc	caaagtatga	tcagggagtg	1320
	gaacctgagc	tcgagccgc	agatgacctg	gatggaggca	cggaggagca	gggagagcag	1380
	ccacaggaga	tgttaagag	gatgggggtt	tatcaagaca	gcattcaaga	caagatttcc	1440
25	gaaaatatga	ggaaggctt	gaccctact	ctatgttcac	cccagagcag	atcatgggaa	1500
	aggatgtcg	gctcctacgc	atcaagaagg	aggatccctt	agacctggcc	ctggaaaggcg	1560
	gtgtggactc	ccccattggg	aagggtgtcg	tttctgtgt	gtatgagcgg	ggagctgtcg	1620
	agcggcatgg	tggattgtg	aaaggggacg	agatcatggc	aatcaacggc	aagattgtga	1680
	cagactacac	cctggctgag	gctgacgctg	ccctgcagaa	ggcctggaaat	caggcgggg	1740
30	actggatcga	ccttgggtt	gccgtctgcc	ccccaaaggaa	gtatgacgt	gagctgaccc	1800
	tcttgcgtaa	gtccaaaagg	ggaaacaaa	ttcacgcgtt	aggaaacagt	gagctccggc	1860
	cccacctcg	gaacacaaag	cctcgacca	gccttgagag	aggccacatg	acacacacca	1920
	gatggcatcc	ttgggacctg	aatctatcac	ccaggaatct	caaactccct	ttggccctga	1980
	accagggcca	gataaggaac	agctcgccc	actttttga	aggccaatgt	ggaggaaagg	2040
35	gagcagcoag	ccgtttggga	gaagatctca	aggatccaga	ctctcattcc	tttcctctgg	2100
	cccagtgaat	ttggtctctc	ccagcttgg	gggactcctt	ccttgaaccc	taataagacc	2160
	ccactggagt	ctctctct	ccatccctct	cctctgccct	ctgctcta	tgctgccagg	2220
	attgtcactc	caaacctac	tctgagctca	ttaataaaat	aaacagattt	atttccagc	2280
	ttaaaaaaaaaa						2289